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Background: Genetic studies have established a causative role for α-synuclein (αS) in Parkinson’s disease (PD), and
the presence of αS aggregates in the form of Lewy body (LB) and Lewy neurite (LN) protein inclusions are defining
pathological features of PD. Recent data has established that extracellular αS aggregates can induce intracellular αS
pathologies supporting the hypothesis that αS pathology can spread via a “prion-like” self-templating mechanism.
Results: Here we investigated the potential for conformational templating of αS intracellular aggregates by seeding
using recombinant wild-type and PD-linked mutant (A53T and E46K) αS in primary mixed neuronal-glial cultures.
We find that wild-type and A53T αS fibrils predominantly seed flame-like inclusions in both neurons and astrocytes
of mixed primary cultures; whereas the structurally distinct E46K fibrils seed punctate, rounded inclusions. Notably,
these differences in seeded inclusion formation in these cultures reflect differences in inclusion pathology seen in
transgenic mice expressing the A53T or E46K αS mutants. We further show that the inclusion morphology is
dictated primarily by the seed applied rather than the form of αS expressed. We also provide initial evidence that
αS inclusion pathology can be passaged in primary astrocyte cultures.
Conclusion: These studies establish for the first time that αS aggregation in cultured cells can occur by a
morphological self-templating mechanism.
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Parkinson’s disease (PD) is the most common move-
ment neurodegenerative disorder [1]. PD belongs to a
spectrum of neurodegenerative diseases, termed α-
synucleinopathies, unified by the presence of the brain
accumulation of neuronal and glial α-synuclein (αS) in-
clusions [2,3]. The physiologic function of αS is still not
completely established; however, αS gene (SNCA) defects
that cause autosomal-dominant PD (SNCA gene dupli-
cation/triplication and missense mutations A30P, E46K,
G51D, H50Q, and A53T) have clearly established a
causal role for αS in disease [4-13]. Differences in the
clinical profiles and pathology of PD patients and mouse
models with either the A53T or E46K mutation have
been documented [4,5,14-16]. In vitro biochemical stud-
ies on amyloidogenic αS fibrils derived from A53T and* Correspondence: bgiasson@ufl.edu; tgolde@ufl.edu
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reproduction in any medium, provided the orE46K missense mutations have also shown differences in
nucleation and elongation of fibril polymerization, pep-
tide structural order, and ultrastructural morphology
[17-21].
Recent postmortem studies in PD patients suggest that
the spread of pathology can occur intercellularly [22-26],
and the induction of αS pathology in experimental
mouse models using intracerebral injection of recombin-
ant αS fibrils suggests that amyloidogenic αS may also
spread by a “prion-like” mechanism [27,28]. A key char-
acteristic of “prion-like” transmission is permissive
templating, in which the amyloidogenic form of the pro-
tein interacts with normal endogenous protein, and that
interaction induces a conformational change in the en-
dogenous protein to an amyloidogenic β-pleated sheet
structure [29,30]. A major difference between “prion-
like” transmission and classical prion disease is paucity
of inter-organism transmission. For many amyloids
this “prion-like” conversion of protein conformation
can often have unique structural and morphologicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has been termed “strain-specific” [29,30].
Taking advantage of previous in vitro observations that
wild-type, A53T, and E46K αS amyloids have distinct
structural properties [17-21,31] and that pathological
inclusions in A53T and E46K transgenic mice are also
distinct [14,15], we used a novel recombinant adeno-as-
sociated virus (rAAV)-mediated αS primary neuronal-
glial culture model to test the hypothesis that fibrillar
A53T and E46K αS may seed cellular inclusions with
unique morphological properties. We show that neur-
onal and astrocytic inclusions formed by fibrillar A53T
and E46K αS are morphologically consistent with those
in transgenic mice and that the seeding fibrils (i.e., A53T
versus E46K αS) have a dominant effect over the αS pro-
tein expressed. We also find that inclusion pathology in-
duced by exogenous fibrils in one astrocyte culture can
be passaged to a second astrocyte culture. This data pro-
vides important support for a conformational templating
of αS inclusion pathology.
Results
Induction of αS aggregates in primary mixed neuronal-
glial cultures
In previous studies, we and others [32-34] have shown
that under experimental conditions that promote the
entry of exogenous recombinant αS fibrils, the formation
of robust Lewy body (LB)-like inclusions can be induced
in cultured cell lines overexpressing human αS. To de-
termine if we could induce inclusion formation in pri-
mary mixed mouse neuronal-glial cultures, we tested
whether overexpression of wild-type human αS mediated
by rAAV2/1 vectors and addition of amino-terminally
truncated exogenous recombinant wild-type (21–140)
αS fibrils was sufficient to induce αS aggregate forma-
tion. We assessed αS aggregate formation using several
previously established methods. First, we used anti-
pSer129 αS antibody immunoreactivity, since αS inclu-
sions are hyperphosphorylated at Ser129 and this modi-
fication is an excellent marker of aggregate formation
[32-37]. However, in primary neuronal cultures used
here this antibody also recognizes a non-αS target local-
ized only in MAP2 positive neuronal processes, as it
stains these processes in cultures from wild-type and
SNCA null mice (Figure 1). Therefore, co-localization of
pSer129 and a second αS antibody, SNL-4, were used to
track inclusion formation. Notably, the SNL-4 antibody
binds the extreme amino terminus of αS. Using seeding
with exogenous 21–140 and full-length αS fibrils, we
previously showed that this antibody also stains the
intracellular inclusions [32,38] and therefore can be used
to distinguish the non-specific neuritic background
staining seen with pSer129. In the primary mixed
neuronal-glial cultures, αS predominantly demonstrated apunctate neuronal staining profile reflecting a presynaptic
distribution (Figure 1A), as previously demonstrated
[39,40]. rAAV2/1-mediated overexpression of αS increased
both the presynaptic and nuclear staining intensity for αS,
but did not affect the neuritic staining of the pSer129 non-
αS target (Figure 1B). Addition of preformed fibrils alone
resulted in pSer129 staining of processes similar to that
seen in blank controls, but this staining did not co-localize
with SNL-4 (Figure 1C). Addition of exogenous fibrils and
overexpression of αS were both required to induce αS ag-
gregate formation (Figure 1D). When robust aggregate
formation is present, the staining of these aggregates with
pSer129 is much more robust then the non-αS target,
therefore the weaker signal of the non-αS target is more
difficult to observe when capturing images that are appro-
priate to visualize pSer129 labeled αS aggregates.
In this system where we overexpressed αS using rAAV2/
1 and added extracellular preformed αS fibrils to induce
intracellular aggregate formation, inclusion formation was
rapid and efficient. Using rAAV2-1 wild-type αS and wild-
type αS fibrils, 0.4±0.1% and 29.1±3.8% of the transduced
cells formed aggregates by 1 and 4 days following fibril
addition, respectively. However, aggregate formation was
accelerated if either E46K or A53T mutant αS was
expressed or used for seeding as demonstrated by the per-
centage of transduced cells with aggregates at 1 day fol-
lowing the addition of fibrils: rAAV2-1 wild type-αS/A53T
fibrils (1.5±0.2%), rAAV2-1 wild type-αS/E46K fibrils (2.6
±1.2%), rAAV2-1 A53T αS/A53T fibrils (16.3±6.7%),
rAAV2-1 A53T αS/E46K fibrils (7.9±2.4%), rAAV2-1
A53T αS/wild-type fibrils (11.9±1.9%), rAAV2-1 E46K αS/
A53T fibrils (3.5±0.6%), rAAV2-1 E46K αS/E46K fibrils
(1.7±0.3%), rAAV2-1 E46K αS/wild type fibrils (3.2±0.6%).
As additional controls to show that seeding with
amyloidogenic αS was required for intracellular ag-
gregate formation, we treated cultures overexpressing
αS with β-synuclein or non-amyloidogenic Δ71-82 αS
(Figure 2) [33,41]. Treatment with either of these pro-
teins did not result in intracellular aggregate formation,
but non-specific pSer129 staining in neuronal processes
was still apparent.
To establish that these pSer129 and SNL-4 immuno-
stained aggregates were bonafide inclusions, we conducted
biochemical fractionation and Western blot analysis previ-
ously used to validate the presence of Triton-insoluble αS
aggregates in culture [32]. As shown in Figure 3A, rAAV-
mediated αS overexpression in combination with the
addition of extracellular αS fibrils induced the formation of
Ser129 hyper phosphorylated Triton-insoluble aggregates.
To validate that extracellular, exogenous aggregates
could enter cells and be incorporated into intracellular αS
inclusions, Thioflavin-S pre-labeled recombinant αS fibrils
were added to cultures and shown to be present within






Figure 1 αS seeded aggregate formation in rAAV2/1-mediated αS expression of mixed neuronal-glial cultures. Double
immunofluorescence with SNL-4 (red) and pSer129 (green): (A) In untreated cultures, αS demonstrated predominantly a punctate staining profile
reflecting a presynaptic distribution, as previously demonstrated [39,40] and (B) rAAV2/1-mediated overexpression of αS increases both the
presynaptic and nuclear staining intensity for αS. In these cultures, pSer129 demonstrates a neuritic staining profile that does not appear to be
due to αS. (C) Addition of fibrils alone resulted in pSer129 staining of processes also seen in blank controls, but not overlapping with SNL-4.
(D) Both rAAV2/1-mediated overexpression of αS and the addition of fibrils resulted in pSer129 immunoreactive inclusions in both the cell body
and processes that overlaps with SNL-4. In cultures derived from SNCA null mice, both (E) untreated and (F) addition of fibrils resulted in a
neuritic staining profile with pSer129, in the absence of SNL-4 staining. The addition of fibrils did not increase the amount of pSer129 neuritic
staining. Cultures were counter stained with DAPI (blue). Bar scale = 100 μm; insets = 25 μm.
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αS aggregate formation; we performed double immuno-
fluorescence with the neuronal specific marker MAP2B
and the astrocyte specific marker GFAP (Figure 4).Inclusion formation was readily observed in both cell
types. In many experiments 4 days post-seeding, more
than 50% of both SNL-4+ MAP2+ neurons and GFAP+
SNL-4+ astrocytes demonstrated pSer129+ aggregates
AB
C
Figure 2 Non-amyloidogenic synuclein proteins do not induce αS inclusion pathology. Double immunofluorescence with SNL-4 (red) and
pSer129 (green): Mixed neuronal-glial cultures with rAAV2/1-mediated overexpression of αS were treated with (A) fibrillar αS, (B) Δ71-82 αS or (C)
β-synuclein. Only treatment with fibrillar αS resulted in Ser129 hyperphosphorylated αS aggregates. Cultures were counter stained with DAPI
(blue). Bar scale = 100 μm; insets = 25 μm.
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combination. By 8 days post-seeding, nearly all cells that
were transduced with the rAAV2/1 αS and were SNL-4+
showed pSer129+ inclusions. As the rAAV2/1 vectors ef-
ficiently transduce greater than 50% of astrocytes and
neurons in culture, these studies reveal that this system
shows remarkable efficiency of inclusion formation. Al-
though αS is predominantly found at higher endogenous
levels in neurons [39,42-44], by using rAAV driven ex-
pression, astrocytes are also as vulnerable to αS aggre-
gate formation.
αS aggregates formed in our cellular system are similar
to those observed in human brains. The inclusions are
partially ubiquitinated and are Thioflavin-S (ThS) posi-
tive (Figures 5 and 6). In cultures treated with rAAV2/1
human wild-type αS, the neuritic staining profile seen
with pSer129 does not overlap with endogenous ubiqui-
tin (Figure 5A). The overexpression of human wild-type
αS (via rAAV2/1) plus exogenous human αS fibrils pro-
duced pSer129+ αS aggregates that co-localize with ubi-
quitin (Figure 5B). Co-localization of ubiquitin staining
with pSer129+ αS aggregates is seen both in neurons
(Figure 5C) and astrocytes (Figure 5D). Similarly,
pSer129+ aggregates show co-localization with ThS
(Figure 6A). The ThS staining profile is seen in both
neurons (Figure 6B) and astrocytes (Figure 6C). How-
ever, it appears that ThS only stains a fraction of thepSer129 immunoreactive inclusions, suggesting that
even within individual cells the structure of the aggre-
gate is not homogenous.
Morphological differences in αS pathology seen in
primary mixed neuronal-glial cultures
Transgenic mouse models for human A53T (line M83)
and E46K (line M47) αS have been developed and char-
acterized [14,15]. Both transgenic models express similar
levels of human αS under the control of mouse prion
protein promoter and develop similar age-dependent
motor phenotypes associated with similar widespread
distribution of neuronal αS inclusions. However, the αS
pathology in the M83 transgenic model predominantly
demonstrates a flame-like somatodendritic and neuritic
profile; whereas, those seen in the M47 transgenic model
have a rounded and compact profile (Figure 7). We
therefore studied the effects that the A53T and E46K
mutations would have on the morphology of αS path-
ology, and whether these differences were due predom-
inantly to the type of protein being overexpressed, the
type of fibril seeding pathology, or both. As seen in
Figure 8A, wild-type, A53T, and E46K αS fibrils are able
to cross-seed αS pathology. Regardless of the protein be-
ing overexpressed, seeding with A53T fibrils overall in-
duced flame-like somatodendritic inclusions that we will
refer to as M83-like pathology; whereas, seeding with
AB
Figure 3 Extracellular αS fibril uptake by cells and formation of intracellular Triton-insoluble αS aggregates. (A) Formation of intracellular
Triton-insoluble αS aggregates induced by extracellular αS amyloid fibrils. Cultures were treated with either rAAV2/1 wild-type αS or rAAV2/1
EGFP (green fluorescent protein control) alone or in combination with wild-type αS fibrils. Four days post-seeding, cultures were biochemically
fractionated using Triton X-100 containing buffer as described in Materials and Methods. Aggregated αS is found in the Triton-insoluble fraction.
Syn211, which recognizes the overexpressed human αS, showed bands in the soluble fractions treated with rAAV2/1 wild-type αS. Only with both
the rAAV2/1-mediated overexpression of human αS plus the addition of extracellular αS fibrils is αS present in the Triton-insoluble fraction.
pSer129, which recognizes the hyperphosphorylated aggregates, also showed a band for αS with both the overexpression of αS plus αS fibrils in
the Triton-insoluble fraction. (B) Z-slice section analysis of αS inclusions showing incorporation of extracellular fibrils into aggregates. Thioflavin-S
pre-labeled wild-type αS fibrils (green) are incorporated into pSer129 aggregates (red). Bar scale = 10 μm.
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Figure 4 αS aggregate formation in neurons and astrocytes. (A) αS pSer129 positive aggregates (green) induced by treatment with
extracellular αS fibrils in cultures with rAAV2/1 human αS expression can occur in neurons as shown by double immunofluorescence with the
neuronal marker MAP2B (red). (B) αS pSer129 positive aggregates (green) induced by treatment with extracellular αS fibrils in cultures with
rAAV2/1 human αS expression can occur in astrocytes as shown by double immunofluorescence with the astrocyte marker GFAP (red). Cultures
were counter stained with DAPI (blue). Bar scale = 25 μm.
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sions that we will refer to as M47-like pathology
(Figures 8 and 9). Blinded quantification also showed
that the morphology of the inclusions was heavily
dependent upon the type of fibril used to seed the cul-
ture and that the ratios of M83 to M47-like pathologies
were significantly different (all p < 0.01). As stated above,
the rAAV2-1 wild-type αS/ wild-type αS fibril combin-
ation showed slower aggregation kinetics relative to
combinations that included a mutant protein, but it
resulted mainly in M83-like pathology; however, when
wild-type was used to seed A53T or E46K αs, the pre-
dominant morphology depended upon the protein being
expressed, suggesting that wild-type αS seeds are more
mutable or heterogeneous (Figure 8B).
Passaging of αS aggregates via cell lysates in astrocyte
cultures
Our studies showed that αS aggregate formation can be
induced in both neurons and astrocytes (Figure 4). Pri-
mary astrocyte cultures have little to no endogenous αS
(SNL-4, Figure 10A) and also lack the background neur-
itic staining of pSer129 (Figure 10A-D). As with the pri-
mary mixed neuronal-glial cultures, the formation of
αS aggregates requires both the overexpression of αS
(via rAAV2/1) and addition of exogenous fibrillar αS
(Figure 10D). For passaging studies, cultures were treated
with rAAV2/1 human wild-type αS and A53T-derived hu-
man αS fibrils.
Cell lysates prepared as described in Material and
Methods from the seeded cultures were added to astro-
cyte cultures overexpressing human wild-type αS (viarAAV2/1). The cultures were left to incubate with the
lysate for 5 days. Cultures exposed to aggregate-
containing cell lysate from the overexpression of human
wild-type αS and seeding with A53T-derived human fi-
brils, showed passaging of pSer129 positive aggregates in
2.9±0.7% of transduced cells (Figure 11A). In contrast,
astrocyte cultures overexpressing human wild-type αS
and seeded with cell lysate from cultures that were
treated with either A53T-derived fibrils (Figure 11B),
rAAV2/1 human wild-type αS (Figure 11C), or nothing
(Figure 11D), did not show any pSer129 and SNL-4 posi-
tive aggregates.
Discussion
αS inclusions are a hallmark pathology seen in PD and
related disorders termed synucleinopathies. Many stud-
ies have indicated that aggregated forms of αS can lead
to neuronal demise [45-48]. Therefore it is important to
better understand the mechanisms involved in αS aggre-
gation to develop tools for therapeutic intervention. Pre-
vious in vitro studies have shown that soluble αS can
efficiently undergo a conformational change into an
amyloidogenic, fibrillar form and it is well established
that in vitro αS aggregation into amyloid is a nucleation
dependent process and can be greatly induced by the
addition of a “seed” or “nucleus” of pre-aggregated αS
[45-47,49,50].
Cellular studies have shown that the entry of a small
amount of preformed αS fibrils into immortalized cell
lines using reagents that promote the entry of these
seeds across the plasma membrane can very efficiently




Figure 5 αS inclusions in the mixed neuronal-glial cultures co-localize with ubiquitin. (A) In cultures treated with rAAV2-1 human wild-type
αS, pSer129 (red) neuritic background staining does not co-localize with endogenous ubiquitin (green). (B) In cultures treated with rAAV2/1
human wild-type αS and exogenous human wild-type αS fibrils, pSer129 (red) hyperphosphorylated αS inclusions in these cultures are
ubiquitinated (green). This ubiquitin staining profile (green) co-localizes with the neuronal marker MAP2B (red, C) and the astrocyte marker GFAP
(red, D). Cultures were counter stained with DAPI (blue). Bar scale = 25 μm.
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reported that the simple addition of extracellular αS fi-
brils to primary neurons can also induce the formation
of intracellular αS inclusions [51]. However, in our pri-
mary neuronal-glial culture system, the addition of only
fibrillar αS resulted in nuclear pSer129 immunoreactivity
with some staining of the processes that did not co-
localize with a marker for endogenous αS (SNL-4), and
this staining was still present in cultures from αS null
mice [52] indicating that it is primarily due to cross-
reactivity. Although it is possible that some of the
pSer129 immunostaining seen in neuritic processes of
the seeded cultures does represent bonafide inclusion
formation, it is imperative that other markers of αS in-
clusion pathology show co-localization with the neuriticpSer129 staining to distinguish inclusion formation from
non-specific pSer129 staining. Indeed, the primary reli-
ance on pSer129 immunostaining in both previous neur-
onal culture studies and in vivo may confound the
interpretation of those studies. Overexpression of αS via
rAAV2/1 plus the addition of fibrillar αS were both
required for the rapid and efficient formation of αS
pathology in our mixed primary neuronal-glial cultures.
These aggregates are composed of endogenous αS, and
share the biochemical properties of LBs and (Lewy
neurites) LNs of being Ser129 hyperphosphorylated,
ubiquitinated, Thioflavin-S positive, and Triton X-100
insoluble. They occur in both neurons and astrocytes in
a high percentage of both cell types. Although LB and
LN pathology in brain tissue samples from PD patients
AB
C
Figure 6 αS inclusions induced in mixed neuronal-glial cultures contain Thioflavin- S positive structures. (A) In cultures treated with
rAAV2/1 human wild-type αS and human wild-type αS fibrils, pSer129 (red) hyperphosphorylated αS inclusions were also ThS positive (green).
This ThS staining profile (green) co-localizes with the neuronal marker MAP2B (red, B) and the astrocyte marker GFAP (red, C). Cultures were
counter stained with DAPI (blue). Bar scale = 50 μm.
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casionally also be within astrocytes along with a massive
astrogliosis surrounding dying neurons in the SNpc of
PD patients [53]. Using a mixed culture model where
pathology is seen in both cell types allows for furtherA
B
Figure 7 Distinct morphological properties of αS inclusions in M83 (A
M83 transgenic mice stained with αS antibody SNL-4 (red) or pSer129 (gre
mice stained with αS antibody SNL-4 (red) or pSer129 (green) show a “roun
DAPI. Bar scale = 25 μm.study of the interplay that may be occurring during the
pathogenesis of PD. Although subtle differences in ex-
perimental paradigms may well-explain the differences
between our study and the Volpicelli-Daley et al. study
where seeded inclusion formation was reported in53T) and M47 (E46K) human αS transgenic mice. (A) Inclusions in
en) show a “flame-like” morphology. (B) Inclusions in M47 transgenic
d-like” compact morphology. Sections were counter stained with
AB
Figure 8 αS mutant specific and dominant morphological induction of αS aggregates. (A) Immunofluorescence analysis of morphological
differences in αS aggregates is predominantly determined by the type of extracellular αS fibril challenge. Cultures were transduced with rAAV2/1
expressing wild-type, A53T, or E46K αS as indicated in each respective panel and described in Materials and Methods. Cultures were then treated
with preformed fibrils comprised of wild-type, A53T, or E46K αS, as indicated in each respective panel. At one day post-seeding (and four days
post-seeding for wild-type-wild-type), cultures were fixed and stained with pSer129 antibody (green) to assess for differences in morphology.
Cells were counterstained with DAPI (blue). Bar scale = 25 μm. (B) Quantification of morphological differences for αS aggregates reveals statistical
differences in inclusion morphology among seeding combinations. One-way ANOVA with Bonferroni correction for comparison of all groups to
each other for flame-like M83 pathology reveals significant differences in inclusion morphology between all A53T fibrillar αS-seeded and E46K
fibrillar αS-seeded (**) cultures, but not with WT and A53T combinations (*). Wild-type-wild-type combination (*) was more likely to result in
M83-like inclusion morphology; however, when wild-type fibrils were used to seed either intracellularly expressed mutant proteins, the mutant
protein predominantly determined inclusion morphology further indicating the dominant effect of the mutant proteins. p < 0.01; n = 6
fields/seeding combination. Values are means ± SD.
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Figure 9 Three-dimensional differences in morphology of αS inclusions. Confocal Z slice analysis midway through the pSer129+ αS
aggregates (green) show that (A) M83-like inclusions derived from rAAV2/1-mediated overexpression of human A53T αS and addition of A53T-derived
human αS fibrils have a diffuse distribution throughout the cell body. In contrast, (B) M47-like inclusions derived from rAA2/1-mediated overexpression





Figure 10 αS seeded inclusion formation in astrocyte cultures. Double immunofluorescence with SNL-4 (red) and pSer129 (green): (A) In
untreated astrocyte cultures, there is very limited endogenous αS expression (SNL-4, red) and no hyperphosphorylated αS (pSer129, green).
(B) rAAV2/1-mediated overexpression of human wild-type αS increases both the cell body and processes staining intensity for αS in the absence
of hyperphosphorylated αS. (C) Addition of human A53T-derived αS fibrils alone showed similar endogenous expression levels of αS compared to
the blank control along with the absence of hyperphosphorylated αS. (D) Both rAAV2/1-mediated overexpression of human wild-type αS and the
addition of human A53T derived αS fibrils resulted in pSer129 immunoreactive inclusions in both the cell body and processes that overlap with
SNL-4. Cultures were counterstained with DAPI (blue). Bar scale = 100 μm; insets = 25 μm.





Figure 11 αS species capable of inducting intracellular αS aggregates can be passaged from cell lysates. (A) Astrocyte cultures with
rAAV2/1-mediated overexpression of human wild-type αS treated with cell lysate from astrocyte cultures containing αS aggregates via
overexpression of human wild-type αS and addition of human A53T- derived αS fibrils. At five days post-seeding, this resulted in pSer129
(green) aggregates in both the cell body and processes, which overlapped with SNL-4 (red). This was compared to astrocyte cultures with
rAAV2/1-mediated overexpression of human wild-type αS and treated with cell lysates from astrocyte cultures treated with human A53T-derived
αS fibrils (B), rAAV2/1-mediated overexpression of human wild-type αS (C), or untreated cultures (D). In the latter 3 conditions, at 5 days
post-seeding there was uniformly distributed overexpression of αS in the absence of hyperphosphorylated αS aggregates (B,C,D). Cultures
were counterstained with DAPI (blue). Bar scale = 100 μm; insets = 25 μm.
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this discrepancy will require further experimental
investigation.
Some post-mortem studies of the distribution of αS
pathology in the brains of PD patients and the induction
of αS pathology in transplanted neurons in the brains of
some PD patients have suggested that αS pathology may
spread from peripheral nerves to the CNS and from the
CNS onto grafted neurons [22-26], but different con-
cepts have been proposed to explain the mechanism of
pathology propagation. These have included: chronic gen-
eralized neuroinflammation, which may promote the up
regulation and subsequent aggregation of αS; oxidativestress triggered by chronic excitotoxicity, which causes
post-translational modifications of αS, such as nitration,
that makes the protein more aggregate prone; loss of
homeostasis from chronic cellular stress, which may
lead to the failure of molecular chaperones and other
machinery to effectively control the level of misfolded
αS; and finally a “prion-like” spread where misfolded αS
is transferred among cells and recruits endogenous αS
into pathologic inclusions [54].
Further support for the notion that αS pathology may
spread in the CNS by intercellular release and re-uptake
of amyloidogenic αS are the recent reports showing that
intracerebral injection of pre-formed recombinant αS
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mice (line M83) into younger healthy M83 transgenic
mice induces αS pathology and motor disease [27,55].
Injection of pre-formed recombinant αS fibrils into wild-
type mice was also recently shown to induce brain
αS aggregation that appears to spread from the site of
injection [28]. These findings suggest that amyloidogenic
αS species can initiate and perhaps lead to transmission
of αS pathology, but the possibility that the other mech-
anisms mentioned above may also be involved cannot
be excluded.
To further investigate the permissive conformational
templating of αS aggregation, we took advantage of the
unique properties of disease-causing mutants A53T and
E46K, which also have unique effects on aggregate for-
mation. Both mutations are found in the amino terminus
of the protein, proximal to the central hydrophobic
stretch (NAC region), which is required for fibrillization
of αS and they accelerate the fibrillization of αS with the
A53T mutation having an increased propensity over the
E46K mutation [18,31,56,57]. The increased aggregation
of these two mutants of αS is due to alterations in the
peptide structural order of αS, which influences mono-
mer folding and may make them more susceptible to ag-
gregation [19,20]. In addition, in vitro polymerized E46K
αS fibrils show district structural and biochemical
features compared to wild-type and A53T αS fibrils
[17-19,31] and these differences are most likely directly
responsible for the different observed morphological
conformations of the αS inclusions in cultured cells and
transgenic mice. Our findings that primary cultures ex-
pressing wild-type, E46K, or A53T αS challenged to
A53T-derived αS fibrils mainly resulted in aggregates
with a flame-like profile, while similar treatment with
E46K-derived αS fibrils primarily induced the formation
of round, compact inclusions demonstrate the conform-
ational templating of αS aggregation in vivo. It is not
clear if the differences in inclusion morphologies result
in any significant altered pathophysiological outcomes
or if they simply reflect different structure variants.
Mice that express E46K or A53T human αS develop
pathological inclusions with these distinct morpho-
logical features, but both types of inclusions are associ-
ated with similar severe motor phenotype resulting in
death [14,15].
These data, along with other evidence that αS path-
ology may to be transmissible [22-24,27,28,58], indicates
that αS aggregation may be able to spread intercellularly
by conformational templating of amyloid formation akin
to a strain-specific prion-like mechanism that has been
documented for other prionoid diseases [29,30]. One dif-
ference between our model and typical prion strain-
specific properties [29,30] is that we studied this
phenomenon for αS using disease-causing mutants,while the same type of process can occur with wild-type
prion proteins. Future studies will investigate whether
unique post-translational modifications of wild-type αS
can also result in “strain-like” conformational templating.
Because both intrinsic perturbations of proteostasis and
inflammatory stimuli can induce αS inclusion formation it
is currently challenging to definitively distinguish between
true seeding of pathology and other factors that may con-
tribute to inclusion formation in vivo [54]. Based on the
morphological seeded templating described here, it should
be possible to distinguish between true exogenous seeding
and other mechanisms of pathology induction in vivo.
We also show that αS pathology can be induced in mul-
tiple CNS cell types, allowing for studies of how the inter-
play between these cells may contribute to disease.
Because of its efficiency, future studies examining both the
prion-like spread and its effect on cellular function can be
facilely carried out using this culture model. Further work
to provide more support for the “prion-like” spread can be
done using this model. One of the characteristics of a
“prion-like” spread is that pathology can be continuously
passaged from an infected to naïve host and that different
prion strains maintain their pathological characteristics
[59]. Although we show that αS aggregation can be pas-
saged from cell lysates derived from astrocytes cultures
seeded with A53T αS fibrils, we are currently expanding
our studies to further investigate this phenomenon. These
studies will help us to elucidate the mechanisms by which
pathology spreads not only in PD but also potentially in
other neurodegenerative disorders and help to study a
means for therapeutic intervention.Conclusion
We report on a novel mixed primary neuronal-glial cul-
ture system that can be used as a robust model of αS ag-
gregate formation. A major advantage of this system is
that we can manipulate both the αS protein expressed
and the type of extracellular seeds added. Using this ex-
perimental system and disease-causing αS mutants, we
show that the addition of extracellular preformed fibrils
can induce conformational templating of intracellular
aggregates and that the nature of mutant fibrils has a
dominant effect on inclusion formation. These studies
provide further credence to the notion that αS pathology
may be able to spread via conformational dependent
self-templating (“prion-like”) mechanisms at least in
terms of intercellular transmission and induction of
change in protein conformation by direct protein inter-
action. If such conformational templating occurs in vivo,
then distinct inclusion morphology induced by distinct
αS may be one surrogate that can be used to distinguish
between seeded templating and other mechanisms of in-
ducing αS pathology in vivo.
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Mixed neuronal-glial primary cultures
All procedures were performed according to the NIH
Guide for the Care and Use of Experimental Animals
and were approved by the University of Florida Institu-
tional Animal Care and Use Committee. SNCA null
mice [52] were obtained from The Jackson Laboratory
(Bar Harbor, MA). Primary cultures were prepared from
P0 C3HBL/6 mouse brains (Harlan Labs). Cerebral cor-
tices were dissected from P0 mouse brains and were dis-
sociated in 2 mg/mL papain (Worthington) and 50 μg/mL
DNAase I (Sigma) in sterile Hank’s Balanced Salt Solution
(HBSS, Life Technologies) at 37°C for 20 minutes. They
were then washed three times in sterile HBSS to inactivate
the papain and switched to 5% fetal bovine serum
(HyClone) in Neurobasal-A growth media (Gibco), which
includes 0.5 mM L-glutamine (Gibco), 0.5 mM GlutaMax
(Life Technologies), 0.01% antibiotic-antimycotic (Gibco),
and 0.02% SM1 supplement (Stemcell). The tissue mix-
ture was then triturated three times using a 5 mL
pipette followed by a Pasteur pipette, and strained
through a 70 μm cell strainer. The cell mixture was then
centrifuged at 200 g for 3 minutes, and re-suspended in
fresh Neurobasal-A media. They were then plated onto
poly-D lysine coated chamber slides (Life Technologies)
or dishes at around 100,000-200,000 cells/cm2. Cells
were maintained in the Neurobasal-A growth media
mentioned above without fetal bovine serum at 37°C in
a humidified 5% CO2 chamber.rAAV2/1 preparation and expression
rAAV serotype 2/1 expressing human wild-type, A53T
or E46K αS under the control of the CMV early enhan-
cer/chicken β actin (CAG) promoter, were generated as
described previously [60]. At 5 days in vitro (DIV),
each virus was added to cultures at a final concentration
of 1011 genome copies/mL. We have determined that
at 12DIV, ~40%+ of cells in our cultures are transduced
by rAAV2-1.Preparation of recombinant αS fibrils
Recombinant, human β-synuclein and 21–140, wild-type,
A53T, E46K, and Δ71-82 αS proteins were expressed
and purified as described previously [31,32,34,41]. For
amyloid assembly 21–140, wild-type, A53T, and E46K
αS proteins (5 mg/mL) were incubated in sterile
phosphate-buffered saline (PBS; Life Technologies,
Carlsbad, CA, USA) at 37°C with continuous shaking at
1050 rpm (Thermomixer R, Eppendorf, Westbury, NY,
USA) and fibril formation was monitored by turbidity
and K114 fluorometry [32]. Fibrils were diluted to
1 mg/mL in sterile PBS and sonicated for 2 hours,
which results in fragmentation into smaller fibrils ofvarying lengths [32,33]. Cultures were treated with
1 μM of fibril mix at 8 DIV.
Fibrils pre-labeled with Thioflavin-S (ThS) were only
used where indicated. A 1 mg/mL fibril mix was incu-
bated in 0.05% ThS for 1 hour then spun at 16,000 g for
5 minutes, and washed with PBS three to five times and
sonicated for 2 hours. Fibril mix was then added to cul-
tures at a final concentration of 1 μM.
Biochemical cellular fractionation and western blotting
analysis
Samples for biochemical analysis were harvested at
4 days post-seeding. Cultures were washed in PBS and
scraped in 1% Tx-100 TBS (50 mM Tris, 150 mM NaCl,
pH 7.4) with protease and phosphatase inhibitors and
placed on ice for 10 min. Lysates were then centrifuged
at 100,000 g for 20 min at 4°C. Supernatants were re-
moved (Triton-soluble fraction), and the pellet was
washed with the TBS buffer and re-centrifuged. The
remaining pellet was then resuspended in 2% SDS, soni-
cated and heated to 100°C for 10 min (Triton-insoluble
fraction). 2% SDS was added to the Triton-soluble frac-
tion that was heated to 100°C. Equal amounts of protein
were resolved by SDS-PAGE on 15% polyacrylamide
gels, followed by electrophoretic transfer onto nitrocellu-
lose membranes. Membranes were blocked in TBS with
5% dry milk, and incubated overnight with Syn211, a
mouse monoclonal antibody specific for amino acids
121–125 in human αS [61], in TBS/5% dry milk, or
pSer129, a mouse monoclonal antibody specific for αS
phosphorylated at Ser129 [35], in TBS/5% bovine serum
albumin (BSA). A total anti-actin antibody (clone C4)
(Millipore, Billerica, MA) was used as a loading control.
Each incubation was followed by goat anti-mouse conju-
gated horseradish peroxidase (HRP) (Amersham Biosci-
ences, Piscataway, NJ). Protein bands were detected using
chemiluminescent reagent (NEN, Boston, MA) and a
FluorChem E and M Imager (Proteinsimple, San Jose,
California).
Immunofluorescence microscopy analysis
Samples for immunofluorescence analysis were taken at
4 days post-seeding (and at 1 day post-seeding where in-
dicated). For double immunofluorescence analysis, cells
were fixed with 4% paraformaldehyde/PBS. Following
PBS washes, cells were blocked with 5% goat serum/
PBS/0.3% Triton X-100 for 1 hour. Cultures were incu-
bated in primary antibodies: pSer129 (1:500) and SNL-4
(1:500), a rabbit polyclonal antibody raised against amino
acid sequence 2–12 of human αS, but that also reacts
with murine αS [61]. Other primary antibodies include
rabbit polyclonal anti-MAP2B (1:100), a neuronal marker
(Millipore); rabbit polyclonal anti-GFAP (1:1000), an astro-
cyte marker (Dako); and rabbit polyclonal anti-ubiquitin
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Alexa-fluor 488 and 594 conjugated secondary antibodies
(1:1000) (Invitrogen). Nuclei were counterstained with
4′,6-diamidino-2-phenylindole (DAPI; Invitrogen), and cov-
erslips were mounted using Fluoromount-G (Southern Bio-
tech, Birmingham, AL). Thioflavin-S (Sigma-Aldrich)
immunostaining was performed after secondary antibody
incubation at a concentration of 0.05% followed by three
washes in 70% ethanol and three washes in water. Images
were captured on a Leica TCS SP2 AOBS Spectral Confocal
Scanner mounted on a Leica DM IRE2 inverted fluorescent
microscope. All images were captured with either 20× or
63× water immersion objectives as projection images from
a Z-stack of <1.0 μm per plane.
Astrocyte cultures
All procedures were performed according to the NIH
Guide for the Care and Use of Experimental Animals
and were approved by the University of Florida Institu-
tional Animal Care and Use Committee. Astrocyte cul-
tures were prepared from P2 C3HBL/6 mouse brains
(Harlan Labs). Cerebral cortices were dissected from P2
mouse brains and were dissociated in 2 mg/mL papain
(Worthington) and 50 mg/mL DNAase I (Sigma) in ster-
ile Hank’s Balanced Salt Solution (HBSS, Life Technolo-
gies) at 37°C for 20 minutes. They were then washed
three times in sterile HBSS to inactivate the papain and
switched to Dulbecco’s Modified Eagle Medium (Life
Technologies) with 10% fetal bovine serum (Life Tech-
nologies) and 100 U/mL Penicillin and 100 μg/mL
Streptomycin (Life Technologies). The tissue mixture
was then triturated three times using a 5 mL pipette
followed by a Pasteur pipette and strained through a 70
μm cell strainer. The cell mixture was then centrifuged
at 200 g for 3 minutes, and re-suspended in fresh
DMEM media. They were then plated in chamber slides,
10 cm culture dishes, or T-75 flasks at 75,000 to 200,000
cells/cm2. Cells were maintained in the DMEM media
mentioned above at 37°C in a humidified 5% CO2 cham-
ber. After two days, flasks were shaken for 30 seconds
and supplied with fresh media. Upon reaching
confluency, flasks were split using TrypLE Express (Life
Technologies) for two generations per original culture.
Cell lysate passaging in astrocyte cultures
Since induction of αS aggregates was seen in both neu-
rons and astrocytes in mixed cultures, astrocyte cultures
were used because they can be split which facilitated the
passaging experiments. The first generation astrocyte
cultures were split into 10 cm culture dishes at 75,000
cells/cm2. rAAV 2/1 expressing human wild-type αS, as
described above, was added at 3 days following plating
at a final concentration of 1011 genome copies/mL. At
5 days following plating, the media was changed andcultures were treated with 1μM αS fibril mix for 5 days.
Cultures were then washed three times in PBS and incu-
bated in 0.25% Trypsin-EDTA (Life Technologies)
for 10 minutes to inactivate residual extracellular αS fi-
brils. Cells were then collected in DMEM and spun at
200 g for 5 minutes. Pellets were rinsed with PBS and
then frozen.
The second generation astrocyte cultures were again
split and were transduced with rAAV 2/1 expressing hu-
man wild-type αS, as mentioned above, for two days.
Then the cell pellets from the first generation cultures
were thawed, re-suspended in 1 mL PBS, and lysated by
sheer force with a 27 g needle. 100 μL of this lysate was
then added to the second generation astrocyte cultures
for 5 days.
Quantitative analysis
Observations of morphological differences in αS were
made by observer blinded, random field counting. Im-
ages were captured with an Olympus BX51 fluorescence
microscope mounted with a DP71 digital camera (Olympus,
Center Valley, PA) using 10× magnification and imaged
were enlarged with Photoshop software and using a grid
to allow for total field counting. For each seeding com-
bination, 6 fields were counted. Criteria for inclusion
morphology were set according to that seen in the M83
and M47 mouse models (see Results Figure 7). Briefly,
either M83-like filling the somatodendritic compart-
ment or M47-like with compact and rounded peri-
nuclear inclusions. Results were expressed as the mean
ratio of cells showing either type of morphology to the
total number of inclusions per field ± SD. Comparisons
for significance were made using one-way ANOVA with
Bonferroni’s post-hoc test in GraphPad Prism software
(San Diego, CA).
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